Insilico Separation Technologies Completes Nearly $10M Series A Funding to Advance Bioseparation Instrumentation

VCBeat (WeChat ID: vcbeat) recently learned that,Inscinstech Completes Nearly $10 Million Series A Financing Round, Led by Matrix Partners China, with Follow-on Investments from Yida Capital and Dynamic Balance Capital. The Funds Will Be Used for New Product R&D, Production Capacity Expansion, and Market Expansion in Europe and the United States.Previously, Inscinstech had secured Pre-A round financing from Dongpingheng Capital.

Inscinstech, established in early 2017, is a high-tech enterprise specializing in bioseparation technologies. The company has secured more than 30 intellectual property rights, including over ten invention patents, and operates three R&D centers in Suzhou, Beijing, and Boston, USA. Its core technical team previously engaged in the development of high-end scientific instruments—such as chromatography, spectroscopy, mass spectrometry, and laser light scattering systems—at leading global scientific instrument companies, mastering key core technologies in liquid chromatography, spectroscopy, and mass spectrometry.

Regarding the second round of financing in 2021, Mr. Li Dawei, founder of Inscinstech, stated:“We would like to extend our sincere gratitude to Matrix Partners China, Yida Capital, and Nanjing Dynamic Balance for their trust and support in Inscinstech. This financing round is of significant importance to Inscinstech, as the company will accelerate its strategic layout in new product development, capacity expansion, and market expansion in Europe and the United States. In the face of severe challenges facing the global biopharmaceutical industry and supply chains, Inscinstech will continue to focus on the biopharmaceutical sector. Through continuous technological innovation, we are committed to reducing reliance on imported high-end life science equipment, achieving localization of core components, and providing comprehensive process separation and analytical testing solutions for biopharmaceutical customers worldwide.”

As the lead investor in the company’s Series A round, Sun Linghao, Investment Director at Matrix Partners China, stated:“We are delighted to have invested in Inscinstech at an early stage. In the field of scientific instruments, we place significant emphasis on foundational innovation and the localization of core components. Inscinstech is one of the few domestic startups that independently develop core equipment for biopharmaceuticals based on chromatography, spectroscopy, and mass spectrometry technology platforms. The company’s products have achieved a leading position in China in the field of laboratory protein purification and have been validated by multiple benchmark customers. We look forward to the company continuously expanding its product portfolio based on its foundational technology platforms, providing global biopharmaceutical customers with high-quality, cost-effective total solutions for scientific research instruments.”

Xue Yi, Senior Partner at Yida Capital, stated:“The rapid development of China’s life sciences and biopharmaceutical industries has increasingly highlighted the value of upstream supply chains. The Inscinstech team brings many years of industrialization experience in areas such as bioseparation and laboratory analysis technologies, and has launched multiple core instruments for application scenarios including protein purification, nucleic acid synthesis, and gene therapy, enabling rapid market entry and swift growth in its customer base. We are optimistic about Inscinstech’s pragmatic business philosophy and its commitment to continuous independent innovation. Under the leadership of Mr. Li, we believe the company is poised to become a well-known supplier of scientific instruments and equipment in the life sciences sector. Yida Capital remains committed to full-industry-chain investment and collaborates with portfolio companies to build industry ecosystems. We will provide ongoing support in customer acquisition and channel development to help drive the company’s growth.”

Zhang Qian, Investment Director at Dongpingheng Capital Medical, stated:“Dongpingheng Capital, as the inaugural institutional investor in Inscinstech’s Series A round, has witnessed the company efficiently achieve independent R&D of core components and large-scale transition to mass production of its equipment, alongside highly effective market promotion and rapid order growth. Under the leadership of Mr. Li, the company has gradually assembled a team of R&D, marketing, production, and management professionals with extensive industry experience in the field of life science instruments and consumables. With this additional investment, Dongpingheng Capital will continue to support the company’s overall R&D and product commercialization plans, aligning with Dongpingheng Capital’s investment portfolio in the biopharmaceutical sector to help Inscinstech become a leading global provider of scientific instruments for the biopharmaceutical industry.”

With the in-depth development of information technology, biomedicine, materials science, and nanotechnology, the demand for scientific instruments in China has achieved breakthroughs in both quality and quantity.

In terms of volume, driven by supportive policies, China’s expenditure on scientific research has maintained rapid growth. Consequently, market demand for upstream scientific research services—including research reagents, laboratory consumables, and instruments and equipment—continues to expand, offering broad prospects. In terms of quality, domestically produced instruments are not on a level playing field with imported ones; key technologies for related scientific instruments remain subject to critical bottlenecks. Dependence on imports is particularly severe for high-end instruments and core components.

In recent years, the Chinese government has introduced multiple policies to strengthen the principal role of enterprises in innovation, encouraging the research and development, engineering, and industrialization of high-end general-purpose and specialized major scientific instruments, with the aim of achieving domestic production of scientific research supplies.

Since its establishment, Inscinstech has closely served biopharmaceutical companies and research institutions both in China and abroad by providing intelligent, cost-effective equipment.In terms of products, Inscinstech has successfully developed and achieved mass production of the Unique Autopure series protein purification systems with fully independent intellectual property rights, the high-performance Unique AutoOligo large-scale nucleic acid synthesizer, and the Unique AutoMCD nanoplasmid assembly system., thoroughly breaking the monopoly held by imported brands.

Image source: Inscinstech

From a sales perspective, sales performance grew rapidly in 2021, with a year-on-year growth rate exceeding threefold.Has established collaborations with over 300 leading biopharmaceutical and vaccine companies, as well as research institutes, including WuXi AppTec, Livzon Pharmaceutical Group, North China Pharmaceutical Group, Wantai BioPharm, Sihuan Pharmaceutical Holdings, Sino Biological, Lunan Pharmaceutical Group, Pulike Biological Engineering, Wens Foodstuff Group, Changchun Institute of Biological Products, Shanghai Jiao Tong University, and Xiamen University.

In the future, Inscinstech will continue to focus on the pharmaceutical sector, providing cost-effective instruments and equipment for biopharmaceutical CMC, and is committed to becoming a leading brand in the field of scientific instruments.

Matrix Partners China, established in 2008, is a leading venture capital firm in the industry with a long-term focus on early-stage and growth-stage investments. It specializes in investing in sectors such as intelligent manufacturing, hard technology, aerospace, mass consumer goods, enterprise services & B2B & trading platforms, and healthcare. Matrix Partners China has invested in over 700 companies to date. Notable portfolio companies include XPeng Motors, Li Auto, Futu Holdings, Guazi Used Cars, Ele.me, Youzan, Ronbay Technology, XGIMI Technology, Momo, PingCAP, Peijia Medical, Career International, Kym Biosciences, LexinFintech, Zihai Guo, Chuanzhi Education, Junshi Biosciences, Simple Love, SiEngine, and iSpace.

Yida Capital was established through the internal mixed-ownership reform of Jiangsu High-Tech Investment Group, a well-established and renowned venture capital firm. It ranks among the industry leaders in terms of industry research capabilities, assets under management (AUM), and investment specialization, making it one of the most influential venture capital institutions in China. As of August 2021, Yida Capital’s management team had overseen a cumulative AUM of RMB 115.5 billion, invested in and supported 1,071 startups, and helped 216 of these companies list on domestic and international capital markets. Over the past three years, Yida Capital has consecutively won awards such as “Annual Chinese Venture Capital Firm,” “Best Chinese Venture Capital Firm,” “Most Competitive Venture Capital Firm,” “Outstanding Achievement Award for Excellent Venture Capital Firms,” and “Top 10 Best Venture Capital Firms” in prestigious rankings published by Zero2IPO Group, CVSource, Securities Times, the China Venture Capital Association, and Forbes, solidifying its position in the top tier of domestic venture capital firms.

Dongpingheng Capital is a core enterprise of the Nanjing Jiangning Technology Venture Capital Group. With government equity participation and support, market-oriented operations, and professional management, it manages multiple government fund-of-funds, venture capital funds, and industry funds, with a total scale exceeding RMB 30 billion, covering all stages from angel investment to venture capital (VC) and private equity (PE). Adhering to the mission of “enhancing the value of valuable assets,” it focuses on addressing market failures, prioritizes serving innovation and entrepreneurship, and creates an “Investment Plus” service model for enterprises.